Diaglip Drug Interactions

Concomitant use of Glimepiride and other sulfonylureas, the following interactions must be considered: Potentiation of the blood-sugar lowering effect and, thus, in some instances hypoglycemia may occur when one of the following medicines is taken, i.e. insulin, oral antidiabetic drugs, ACE inhibitors, allopurinol, anabolic steroids and male sex hormones, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluoxetine, guanethidine, ifosfamide, MAO inhibitors, miconazole, para-aminosalicylic acid, pentoxifylline (high dose parenteral), phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolones, salicylates, sulfinpyrazone, sulfonamides, tetracyclines, tritoqualine, trofosfamide.
Weakening of the blood-sugar-lowering effect and, thus, raised blood sugar levels may occur when one of the following medicines is taken, i.e. acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine (adrenaline) and other sympathomimetic agents, glucagon, laxatives, (after protracted use), nicotinic acid (in high doses), oestrogens and progestogens, phenothiazines, phenytoin, rifampicin, thyroid hormones.
H₂-receptor antagonists, clonidine and reserpine may lead to either potentiation or weakening of the blood-sugar-lowering effect.
Beta-blockers decrease glucose tolerance. In patient with diabetes mellitus, this may lead to deterioration of metabolic control. Beta-blockers may increase the tendency to hypoglycemia.